AURORA, Colo.– Researchers at the University of Colorado Anschutz Medical Campus and collaborators across the country have conducted the largest and most diverse study of men with extra X or Y chromosomes in the US using a large dataset of military veterans. The results could lead to better diagnoses of...
Latest News
Barcelona, Spain – Published in Clinical Cancer Research, results of a preclinical study led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Stem Cells and Cancer Group, headed by Héctor G. Palmer, pave the way for systemic targeted therapy in patients with pseudomyxoma peritonei, a rare form of...
LEIDEN, Netherlands — Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced a $60 million (€54 million) Series B financing. The financing was led by new investor Ackermans & van Haaren (AvH) with existing co-leads Droia Ventures, EQT Life Sciences and Kurma Partners...
STOCKHOLM, SWEDEN – Vicore Pharma Holding AB, today announced multiple presentations at the 2024 American Thoracic Society (ATS) International Conference, including an oral late-breaking presentation of the final Phase 2a AIR data of buloxibutid in patients suffering from idiopathic pulmonary fibrosis (IPF). “We are pleased to showcase a series of...
GOTHENBURG, Sweden – Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces top line data from a phase II study of its oral angiotensin II type 2 receptor (AT2R) agonist C21 in patients with systemic sclerosis...
CLEVELAND – ViewRay, Inc. (NASDAQ: VRAY) today announced, in recognition of Pancreatic Cancer Awareness Month, more than 2,300 pancreatic cancer patients have been treated with MRIdian at 46 centers around the world. ViewRay would like to recognize the global clinical teams providing options for patients who otherwise may not have...
MUNICH, Germany — ViGeneron GmbH, a next-generation clinical-stage gene therapy company, today announced that the first patient has been dosed in its Phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as...
Watertown, Mass. — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on doses greater than 20 mg/kg for VGL101 in its...
CAMBRIDGE, Mass. – Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced today the enrollment of the first subject in a natural history study dedicated to patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). ALSP is a rare, genetically...
WATERTOWN, Mass. — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced multiple oral and poster presentations on adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) at the 2023 American Academy of Neurology (AAN)...